NGS in Medicine
November 5-6, 2013 | Boston Marriott Cambridge | Cambridge, MA
The latest developments in NGS technologies provide opportunities for clinicians and drug developers to guide patient care, improve clinical development, and advance personalized medicine. But adoption of NGS tests in the clinic requires assay development, clinical and analytical validation, CLIA certification, quality control, and standards development. Cambridge Healthtech Institute’s Inaugural Next-Generation Sequencing in Medicine meeting will address assay development and validation, case studies in using NGS in clinical care, utility of sequencing in clinical drug development, regulatory and reimbursement issues, as well as potential of NGS as companion diagnostics.
- NGS as a clinical test: assay development, validation and quality control
- Clinical utility of sequencing in guiding patient care
- Interpretation of clinical NGS data
- Utility of NGS in drug development and clinical trials
- Diagnostic potential of whole genome sequencing
- Role of NGS in advancing personalized medicine
Scientists who wish to present their knowledge and expertise to their colleagues are asked to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.
If you are interested in presenting, please click here to submit your proposal.
Deadline for submission is Friday, May 3, 2013
For more information, please contact:Julia Boguslavsky
Executive Director, Conferences
For sponsorship information, please contact:Ilana Quigley
Manager, Business Development